Molecular Mechanism Analysis of Inflammasomes in Stroke

The inflammasome is a multiprotein complex that mediates neuroinflammation and contributes to neuronal cell death in ischemic stroke. Different inflammasomes such as the NLRP1, NLPR3, AIM2, and NLRC4 inflammasomes are involved in mediating the inflammatory response through the activation of interleukin (IL)-1β and IL-18 as well as the inflammasome-mediated pyroptotic cell death. Somatic suppression is associated with improved outcomes (reduced infarct volume, reduced inflammation, and improved functional recovery) in animal models of stroke. The NLRP3 inflammasome has become an ideal therapeutic target due to its important role in the inflammatory response after ischemic stroke.

Fig. 1. The NLRP3 inflammasome plays an important role in the inflammatory response after ischemic stroke.Fig. 1. Involvement of the NLRP3 inflammasome in the pathophysiological processes following ischemic stroke. (Feng et al., 2020)

Our Services

At Ace Therapeutics, we focus on analyzing the role of NLRP inflammasome-mediated signaling in the pathophysiology of stroke and helping our clients develop stroke therapies targeting NLRP inflammasome-related signaling. Our team of highly skilled researchers and experts in the field of neuroinflammation uses cutting-edge technologies and multidisciplinary approaches to study the role of NLRP3 inflammasome in in vitro and animal models of ischemic stroke.

Identifying and Validating Inflammasome-associated Targets for Stroke

We can analyze the multiple pathways that regulate NLRP3 inflammasome activation and inhibition in stroke to identify potential therapeutic targets.

  • Nrf2HO-1/NLRP3 signaling
  • TLR4/NLRP3 signaling
  • Sirt-1 signaling
  • MAPK pathway
  • P13K/AKT pathway
  • NF-KB/NLRP3 axis
  • AMPK/GSK-33 signaling
  • Parkin-dependent mitophagy pathway
  • NF-κB p65 signaling
  • PTEN and the PI3K/Akt/GSK-3β signaling

Developing Stroke Drug Targeting NLRP3 Inflammasome Pathway

Our experts can help clients develop new therapeutic strategies for stroke to allow targeting upstream or downstream of the NLRP3 inflammasome pathway, such as the inflammasome NLRP3 complex, the core proteins involved in the MAPK and NF-κB pathways, IL-1β and IL-18 and their respective receptors and plasma membrane channels. We aim to accelerate the development process of direct and indirect inhibitors of NLRP3 inflammatory vesicles for clients.

Analyzing the Efficacy of Stroke Drug Targeting NLRP3 Inflammasomes

We can assess the impact of NLRP3 deficiency on BBB damage and infarct volume in animal models of ischemic stroke based on Evans Blue permeability, magnetic resonance imaging (MRI), and electron microscopy analyses. We offer comprehensive services to analyze the effects of stroke drugs on neurological deficits, infarct volume, and brain edema in ischemic stroke through the NLRP3 pathway.

Ace Therapeutics provides reliable services to analyze the molecular mechanisms of NLRP3 inflammasome in ischemic stroke and discover new therapeutic targets for the treatment of ischemic stroke. We work closely with clients to provide customized solutions to meet the unique requirements of each research project. If you are interested in our services, please do not hesitate to contact us!

  1. Feng, Y. S., et al. (2020). Inhibition of NLRP3 inflammasome: a prospective target for the treatment of ischemic stroke. Frontiers in Cellular Neuroscience, 14, 155.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket